|
End-of-day quote
2026-09-18
|
5-day change
|
1st Jan Change
|
|
229.13 CHF
|
-1.98%
|
 |
+0.52%
|
-
|
|
Sep. 17 |
Charles River Laboratories International Introduces Rapid Cell Banking Programs with Next-Generation Sequencing Characterization
|
CI
| |
Sep. 17 |
Argus Research Adjusts Charles River Laboratories International PT to $330 From $250, Maintains Buy Rating
|
MT
| |
Sep. 17 |
Charles River Leverages Expertise in Rapid and In Vitro Methods to Reduce Cell Banking Timelines
|
BU
| |
Sep. 16 |
Charles River Laboratories to Provide Update on New Approach Methodologies Strategy on Investor Day, RBC Says
|
MT
| |
Sep. 15 |
Charles River Laboratories International, Inc. Presents at 2026 Global Healthcare Conference, Sep-15-2026 09:40 AM
| | |
Sep. 14 |
Charles River Laboratories International, Inc. Presents at Morgan Stanley 24th Annual Global Healthcare Conference, Sep-14-2026 10:00 AM
| | |
Sep. 11 |
Charles River Laboratories to Present at Morgan Stanley and Baird Conferences
|
BU
| |
Sep. 11 |
Evercore ISI Adjusts PT on Charles River Laboratories International to $320 From $300, Maintains Outperform Rating
|
MT
| |
Sep. 09 |
Charles River Modernizes Endosafe(R) Endotoxin Testing Cartridge Manufacturing with Fully Automated Production Suite
|
AQ
| |
Sep. 08 |
Charles River Laboratories International Implements Endosafe Cartridge Technology Automated Manufacturing Suite
|
CI
| |
Sep. 08 |
Charles River Modernizes Endosafe® Endotoxin Testing Cartridge Manufacturing with Fully Automated Production Suite
|
BU
| |
Aug. 20 |
Charles River Laboratories International Insider Sold Shares Worth $599,711, According to a Recent SEC Filing
|
MT
| |
Aug. 20 |
Charles River, Medigen Partner on Multivalent Enterovirus Vaccine
|
MT
| |
Aug. 20 |
Charles River Laboratories and Medigen Vaccine Biologics Corp Collaborate to Advance New Vaccine Development Programs Through Next Generation Sequencing
|
BU
| |
Aug. 13 |
Charles River Laboratories International Insider Sold Shares Worth $1,038,657, According to a Recent SEC Filing
|
MT
| |
Aug. 10 |
TD Cowen Adjusts PT on Charles River Laboratories International to $300 From $235, Maintains Buy Rating
|
MT
| |
Aug. 10 |
Rothschild & Co Redburn Adjusts PT on Charles River Laboratories International to $318 From $241, Maintains Buy Rating
|
MT
| |
Aug. 06 |
Charles River Laboratories International Insider Sold Shares Worth $1,327,098, According to a Recent SEC Filing
|
MT
| |
Aug. 06 |
Barclays Adjusts Price Target on Charles River Laboratories International to $300 From $220
|
MT
| |
Aug. 06 |
RBC Adjusts PT on Charles River Laboratories International to $282 From $215, Keeps Outperform Rating
|
MT
| |
Aug. 06 |
Deutsche Bank Adjusts Charles River Laboratories International PT to $300 From $260, Maintains Buy Rating
|
MT
| |
Aug. 06 |
JPMorgan Upgrades Charles River Laboratories International to Overweight From Neutral, Adjusts PT to $310 From $180
|
MT
| |
Aug. 05 |
Top Midday Gainers
|
MT
| |
Aug. 05 |
Charles River Laboratories International, Inc., Q2 2026 Earnings Call, Aug 05, 2026
| | |
Aug. 05 |
Tranche Update on Charles River Laboratories International, Inc.'s Equity Buyback Plan announced on November 5, 2025.
|
CI
|
No results match your criteria Select your edition All financial news and data tailored to specific country editions | 
